MARKET

HURA

HURA

TuHURA Biosciences
NASDAQ
2.130
+0.020
+0.95%
After Hours: 2.130 -0.019 -0.88% 16:15 08/31 EDT
OPEN
2.120
PREV CLOSE
2.110
HIGH
2.230
LOW
2.075
VOLUME
233.41K
TURNOVER
--
52 WEEK HIGH
3.430
52 WEEK LOW
0.4100
MARKET CAP
136.95M
P/E (TTM)
-3.9974
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Top Healthcare Picks: CVS Health (CVS), TuHURA Biosciences (HURA)
TipRanks · 5d ago
Weekly Report: what happened at HURA last week (0817-0821)?
Weekly Report · 08/24 10:27
TuHURA Biosciences Expands Use of Revolving Credit Facility
TipRanks · 08/21 21:31
TuHURA Biosciences Reports Results of 2026 Annual Meeting
TipRanks · 08/19 21:31
Robert Burns Reiterates Buy on TuHURA Biosciences, Sets $10 Price Target Backed by Clinical Milestones and Strong Cash Runway
TipRanks · 08/19 10:26
Weekly Report: what happened at HURA last week (0810-0814)?
Weekly Report · 08/17 10:28
TuHURA Biosciences Extends Runway as Immuno-Oncology Pipeline Advances
TipRanks · 08/15 01:02
TuHURA Biosciences Q2 EPS $(0.14) Beats $(0.15) Estimate
Benzinga · 08/14 12:04
More
About HURA
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. It is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. It is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.

Webull offers TuHURA Biosciences Inc stock information, including NASDAQ: HURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HURA stock methods without spending real money on the virtual paper trading platform.